Search

Researchers studied the link between medicines and brain function among people with HIV. Non-HIV medicines like sedatives and anticholinergic drugs were linked to cognitive difficulties.…

This page highlights hepatitis C resources for service providers working with immigrants and newcomers from countries where higher rates of hepatitis C are common.

Trends in hepatitis C treatment using provincial-level data from 2012 to 2023.

Placeholder

An overview of Canadian resources on HIV, harm reduction and related resources for African, Caribbean and Black communities.

Syphilis has been on the rise in Canada, and around the world, for many years. Though it is preventable and curable syphilis outbreaks continue across the country. The following list of resources can…

These guidelines were developed specifically for Ontario to help reach the undiagnosed.

The Manifesto provides guidelines for conducting Black-focussed HIV-related research and supporting effective policies and programs for Black diasporic people in Canada.

Long-acting HIV pre-exposure prophylaxis (PrEP) is now covered by some drug plans in Canada. Cabotegravir is the first long-acting injectable form of PrEP approved by Health Canada. This highly…

This information session explores the efficacy of doxyPrEP (doxycycline pre-exposure prophylaxis) and doxyPEP (doxycycline post-exposure prophylaxis) as biomedical prevention strategies for reducing…

As people with HIV age, their burden of non-HIV medications can increase. Researchers found that more than 50% of older adults with HIV take at least five non-HIV drugs. Taking five or more non-HIV…

We reviewed the available scientific evidence to determine if routine HIV testing in primary care settings improves HIV testing outcomes.